Skip to main content
Fig. 6 | Cell Communication and Signaling

Fig. 6

From: Novel neoplasms associated with syndromic pediatric medulloblastoma: integrated pathway delineation for personalized therapy

Fig. 6

Pathway activation and therapeutic targeting in LFS (A) and FAP (B) syndromic tumors. The driver growth pathways are encircled in red if they are clinically targetable by pharmacological inhibitors (Inh); in blue, when either there are no clinically approved therapies or the therapeutic intervention is likely to be ineffective, the latter marked by an “X”; and in purple when potential inhibitors may be considered. Gray encircling and “X” marks absence of usually targetable pathways in the LFS atypical prolactinoma. The therapeutic interventions in the management of the tumors are indicated in green: GTR, gross total resection; IR, ionizing radiation; Chemo, chemotherapy

Back to article page

Cell Communication and Signaling

ISSN: 1478-811X